Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 23.75.
Forward PE Ratio (23.75) = Close Price ($21.38) / Consensus Forward EPS ($0.88)
FORWARD PE RATIO
23.75
SECTOR MEDIAN · HEALTHCARE
20.09
median of 67 covered companies
CURRENT VS SECTOR MEDIAN
+18.22%
vs the sector median at left
NRC Health
Market Cap
$481.83M
Forward PE Ratio
23.75
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| NRC Health (NRC) | $481.83M | 23.75 |
| Shoulder Innovations, Inc. (SI)vs › | $407.09M | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.24B | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.33B | 8.22 |
| TransMedics Group, Inc. (TMDX)vs › | $3.09B | 56.94 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.81B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $7.25B | 25.07 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.59B | 36.77 |
| Tempus AI, Inc. (TEM)vs › | $9.76B | N/A |
| Insulet Corp. (PODD)vs › | $10.02B | 21.93 |
Trailing P/E
82.8
reported TTM EPS
Forward P/E
23.8
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.88 implies +252.0% EPS growth vs the reported trailing $0.25.
At today's $21.38 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.88 | $0.88 – $0.88 | 1 | 24.3x |
| 2027-12-31 | $1.11 | $1.11 – $1.11 | 1 | 19.3x |
| 2028-12-31 | $1.16 | $1.16 – $1.16 | 1 | 18.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
